Filtered By:
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 95 results found since Jan 2013.
Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies
Biomed Pharmacother. 2023 Jul 31;165:115242. doi: 10.1016/j.biopha.2023.115242. Online ahead of print.ABSTRACTBladder cancer (BC) is a common and serious type of cancer that ranks among the top ten most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the aggressive nature of cancer cells, and their resistance to medication, managing this disease has become a growing challenge in clinical care. Long noncoding RNAs (lncRNAs) are a group of RNA transcripts that do not code for proteins and are more than 200 nucleotides in length. They play a significant role in controlling cellular pathways and molecu...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 2, 2023 Category: Drugs & Pharmacology Authors: Amirreza Mehmandar-Oskuie Kasra Jahankhani Arman Rostamlou Sepideh Arabi Zahra Sadat Razavi Amirhossein Mardi Source Type: research
A comprehensive review on the composition, biogenesis, purification, and multifunctional role of exosome as delivery vehicles for cancer therapy
Biomed Pharmacother. 2023 Jun 29;165:115087. doi: 10.1016/j.biopha.2023.115087. Online ahead of print.ABSTRACTAll forms of life produce nanosized extracellular vesicles called exosomes, which are enclosed in lipid bilayer membranes. Exosomes engage in cell-to-cell communication and participate in a variety of physiological and pathological processes. Exosomes function via their bioactive components, which are delivered to target cells in the form of proteins, nucleic acids, and lipids. Exosomes function as drug delivery vehicles due to their unique properties of innate stability, low immunogenicity, biocompatibility, biodi...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 1, 2023 Category: Drugs & Pharmacology Authors: Jian Li Ye Zhang Pei-Yu Dong Guo-Ming Yang Sangiliyandi Gurunathan Source Type: research
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Biomed Pharmacother. 2023 Mar 22;161:114567. doi: 10.1016/j.biopha.2023.114567. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is a lack of optimal biomarkers for the prediction of response to this therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, termed zinc finger Asp-His-His-Cys-type palmitoyltransferases (ZDHHC), which precisely control vari...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 24, 2023 Category: Drugs & Pharmacology Authors: Zhiqing Lin Keke Huang Hui Guo Manli Jia Qiuqin Sun Xuhao Chen Jianmin Wu Qingqing Yao Peng Zhang Sergii Vakal Zhengzhi Zou Haiyao Gao Lei Ci Jiangfan Chen Wei Guo Source Type: research
The paradigm of miRNA and siRNA influence in Oral-biome
Biomed Pharmacother. 2023 Jan 20;159:114269. doi: 10.1016/j.biopha.2023.114269. Online ahead of print.ABSTRACTShort nucleotide sequences like miRNA and siRNA have attracted a lot of interest in Oral-biome investigations. miRNA is a small class of non-coding RNA that regulates gene expression to provide effective regulation of post-transcription. On contrary, siRNA is 21-25 nucleotide dsRNA impairing gene function post-transcriptionally through inhibition of mRNA for homologous dependent gene silencing. This review highlights the application of miRNA in oral biome including oral cancer, dental implants, periodontal diseases...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 22, 2023 Category: Drugs & Pharmacology Authors: Adrija Sinha Rahul Bhattacharjee Basudha Bhattacharya Aditya Nandi Ramya Shekhar Ankit Jana Koustav Saha Lamha Kumar Swadheena Patro Pritam Kumar Panda Nagendra Kumar Kaushik Mrutyunjay Suar Suresh K Verma Source Type: research
SOX2 function in cancers: Association with growth, invasion, stemness and therapy response
Biomed Pharmacother. 2022 Oct 19;156:113860. doi: 10.1016/j.biopha.2022.113860. Online ahead of print.ABSTRACTCancer is a leading cause of death worldwide and around 10 million deaths in 2020 were related to cancer. There are a number of therapeutic modalities for cancer such as chemotherapy, radiotherapy and surgery. However, tumor cells have capacity of developing resistance to chemotherapy and radiotherapy. Genetic mutations participate in development and progression of cancer. The current review focuses on the role of SOX2 transcription factor in cancer. SOX2 has capacity of increasing growth and metastasis of cancer c...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 22, 2022 Category: Drugs & Pharmacology Authors: Sepideh Mirzaei Mahshid Deldar Abad Paskeh Maliheh Entezari Seyed Reza Mirmazloomi Aria Hassanpoor Maryam Aboutalebi Shamin Rezaei Elahe Sadat Hejazi Amirabbas Kakavand Hajar Heidari Shokooh Salimimoghadam Afshin Taheriazam Mehrdad Hashemi Saeed Samarghan Source Type: research
Molecular mechanism of the uptake and toxicity of EGF-LipoAgNPs in EGFR-overexpressing cancer cells
Biomed Pharmacother. 2022 Jun;150:113085. doi: 10.1016/j.biopha.2022.113085. Epub 2022 May 10.ABSTRACTThe surface of silver nanoparticles (AgNPs) is characterized by high reactivity resulting in prooxidative and cytotoxic properties. These effects are observed both in normal and in cancer cells, which overexpress the Epidermal Growth Factor Receptor (EGFR). In our previous paper, we have demonstrated that, with the use of liposomes labeled with the Epidermal Growth Factor (EGF), it is possible to direct the toxic effect of AgNPs in EGFR-overexpressing cells. Unfortunately, the mechanism of uptake and toxicity induction by ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 5, 2022 Category: Drugs & Pharmacology Authors: Bartosz Sk óra Konrad A Szychowski Source Type: research
Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma
Biomed Pharmacother. 2022 Mar 31;149:112888. doi: 10.1016/j.biopha.2022.112888. Online ahead of print.ABSTRACTSynovial sarcoma is typical aggressive malignant without satisfactory treatment outcome in adult series. Cyclin-dependent kinases (CDKs) in transcription have been considered promising molecular targets in cancer. Among these, CDK7 has been shown to play important roles in the pathogenesis of malignancies. However, the modulation mechanism of CDK7-regulated transcription in synovial sarcoma is unknown. In the present study, we aim to determine the expression and function of CDK7 in the transcription cycle of RNA po...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 3, 2022 Category: Drugs & Pharmacology Authors: Xiaoyang Li Dylan C Dean Jin Yuan Thomas H Temple Jonathan C Trent Andrew E Rosenberg Shengji Yu Francis J Hornicek Zhenfeng Duan Source Type: research
SiRNA-circFARSA-loaded porous silicon nanomaterials for pancreatic cancer treatment via inhibition of CircFARSA expression
In this study, we designed and synthesized a small interfering RNA (siRNA, named siRNA-circFARSA), which specifically inhibits circFARSA expression. Using liposomes and porous silicon nanoparticles (pSiNPs) as siRNA delivery system, we prepared liposome-siRNA-circFARSA and pSiNP-PEI-siRNA-circFARSA and investigated their anti-cancer mechanism by quantitative real-time PCR and western blotting. Cell proliferation curves and transwell migration assays were performed to investigate the effect of siRNAs proliferation and migration capabilities of cancer cells. Patient-derived tumor xenograft mouse models were used to investiga...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 1, 2022 Category: Drugs & Pharmacology Authors: Huixiao Yuan Xin Huang Qingqing Li Cici Luo Chenyu Lin Shuxian Zhang Yaguang Zhang Zhilin Yan Ning Du Zhongmin Liu Hua Jiang Bingdi Chen Source Type: research
EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
Biomed Pharmacother. 2021 Dec 11;146:112532. doi: 10.1016/j.biopha.2021.112532. Online ahead of print.ABSTRACTBrain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, gliobla...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 15, 2021 Category: Drugs & Pharmacology Authors: Mahshid Deldar Abad Paskeh Atefeh Mehrabi Mohammad Hossein Gholami Amirhossein Zabolian Ehsan Ranjbar Hossein Saleki Adnan Ranjbar Mehrdad Hashemi Yavuz Nuri Ertas Kiavash Hushmandi Sepideh Mirzaei Milad Ashrafizadeh Ali Zarrabi Saeed Samarghandian Source Type: research
